ALISO VIEJO, Calif., Nov. 27, 2013 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCBB:CNSO) announced today it will present at the Sixth Annual LD MICRO Conference on Thursday, December 5, 2013, at 12:00 noon (PT) at the Luxe Sunset Bel Air, Los Angeles, California.
CNS Response (CNS) is a clinical decision support company with a patented commercial neurometric platform, PEER Online, to predict drug response for treatment of brain disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder. Using PEER Technology, CNS is currently performing a 2,000 subject trial at Walter Reed National Military Medical Center focusing on depression, post-traumatic stress disorder ("PTSD") and mild traumatic brain injury ("mTBI").
CNS leadership will be available during the conference for one-on-one meetings. George Carpenter, President and CEO of CNS will present an overview of the Company's technology and growth opportunities.
The LD MICRO Conference highlights microcap companies overlooked by institutional investors and has steadily grown each year since its inception in 2008 with over 1,000 attendees at last year's event. It is expecting 234 micro-cap companies presenting at its 2013 conference.
About CNS Response
CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. Treatment for mental disorders has doubled in the last 20 years, and use of medications has grown over 400% -- but treatments fail more often than they succeed and over 17 million Americans have failed two or more medication therapies for their mental disorder. The company's Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 36,000 outcomes for 9,500 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, the dominant approach for treatment resistant patients.
To discover more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response at PEERinfo@cnsresponse.com.
About LD MICRO
LD Micro is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The firm also hosts the LD MICRO Micro-Cap Growth Conference for investors in December of each year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by most institutional investors. It is a non-registered investment advisor. For more information on the list of presenting companies or to register for the event, please contact (408) 457-1042 or visit www.ldmicro.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
CONTACT: Investor Relations: Marty Tullio, Managing Partner McCloud Communications, LLC 949.632.1900 firstname.lastname@example.orgSource:CNS Response